4P-PHARMA
29.4.2024 06:41:26 CEST | Business Wire | Press release
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/
(Graphic: Business Wire)
With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.
Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."
This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.
This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.
Revital Rattenbach concludes: "After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Site internet : https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma/
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424933193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SWISSto12 passes critical design review of dual-band 5G antennas for UNIVITY satellites9.11.2026 09:00:00 CET | Press release
The milestone clears the way for flight hardware production, bringing UNIVITY closer to delivering both broadband and direct-to-device 5G services from a single satellite architecture. SWISSto12, a leading enabler of the new space economy, today announced it has passed the Critical Design Review (CDR) for the S- and Ka-band phased array antennas for UNIVITY’s 5G non-terrestrial network (NTN) demonstration satellites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109823601/en/ SWISSto12's S- and Ka-band phased array antennas pass Critical Design Review SWISSto12 is developing two active antennas for UNIVITY: an S-band direct radiating array (DRA) for direct-to-device services, connecting standard 5G phones straight to the satellite, and a Ka-band DRA operating at 26 GHz for broadband services and feeder links. Both are built for 5G NTN applications, allowing one single satellite to carry both broadband and direct-to-devic
Arrow Electronics lancerer en ny forretning, Capstone, for at øge fokus på IP&E-løsninger9.11.2026 07:00:00 CET | Pressemeddelelse
Arrow præsenterer den nye forretning på electronica-messen i München (10.-13. nov) Arrow Electronics, Inc. (NYSE:ARW) annoncerede i dag lanceringen af Capstone, en global forretning dedikeret til interconnect, passiver og elektromekaniske (IP&E) produkter, løsninger og services. Med Capstone skaber Arrow en fokuseret og specialiseret go-to-market-tilgang for IP&E idet det teknologisegment bliver mere kritisk for systemets ydeevne, pålidelighed og forsynings sikkerhed. Capstone er designet til at gøre IP&E nem at specificere, indkøbe og skalere. Kunder vil få fordelen ved dedikeret IP&E ressourcer, hurtig beslutningstagning og bred teknisk viden, både på on-board og off-board produkter. Med et fokuseret brand kan Capstone tilbyde kunderne mere målrettet rådgivning og støtte gennem hele processen – fra de første designovervejelser til den færdige produktion. Det giver kunderne et bedre grundlag for at træffe de rigtige beslutninger, mindske risikoen undervejs og skabe de bedste skalerbar
Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro® in Europe9.11.2026 07:00:00 CET | Press release
Zemcelpro is authorised in the European Union for eligible adults with blood cancers who need an allogeneic stem cell transplant and have no other suitable donor cells available. Avanzanite secures exclusive commercialisation rights to Zemcelpro across 32 countries covering the European Economic Area, UK and Switzerland including potential indication expansion. Avanzanite will become the EU marketing authorisation holder following regulatory transfer and support a planned Phase 3 trial. Zemcelpro becomes Avanzanite’s fifth rare disease launch and first advanced therapy medicinal product (ATMP). Avanzanite Bioscience B.V. (“Avanzanite” or “Company”) a European pharmaceutical company focused on rare diseases, today announced an exclusive licence agreement with Montreal-based Cordex Biologics, an ExCellThera company (“ExCellThera”), a leader in enhanced blood stem cell therapies, to commercialise Zemcelpro®. Zemcelpro received conditional marketing authorisation from the European Commissi
GigaDevice to Showcase Intelligent Embedded Solutions at electronica 20269.11.2026 07:00:00 CET | Press release
Experience Intelligent Motion Through Real-World Applications in Robotics, Industrial, Automotive, and Computing GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will showcase its latest embedded technologies and application-oriented solutions at electronica 2026. As the company continues to strengthen its presence in Europe, the exhibition provides an opportunity to engage with regional customers and partners and demonstrate solutions addressing evolving needs across industrial automation, automotive electronics, and intelligent computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261108191898/en/ Experience Intelligent Motion at Electronica Munich “Europe is an important market for GigaDevice, with strong demand for innovation across industrial automation and automotive electronics,” said Dr. Reiner Jumpertz, Vice President and Gene
Sceye og SoftBank Corp. indgår aftale om en flåde af stratosfæriske platforme, der skal sikre dækning i hele Japan9.11.2026 02:38:00 CET | Pressemeddelelse
Den femårige aftale bygger videre på Sceyes vellykkede test af stratosfærisk forbindelse i Japan og tager et skridt nærmere fuld udrulning af HAPS som stratosfærisk infrastruktur og som en hjørnesten i SoftBanks strategi om et allestedsnærværende netværk Sceye, en amerikansk virksomhed inden for rumfart og materialeteknologi, der udvikler højtflyvende platformssystemer (HAPS) til infrastruktur i stratosfæren, annoncerede i dag en femårig rammeaftale (MSA) med SoftBank Corp. (TOKYO:9434, "SoftBank") om at fremstille, opsende og drive en flåde af Sceyes HAPS-platforme over Japan med det mål at opnå dækning i hele landet. Aftalen videreudvikler virksomhedernes partnerskab fra demonstrationsflyvninger til fuldt udbygget infrastruktur i stratosfæren. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261103165280/da/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom